Technical Analysis for IKNA - Ikena Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.38 | 3.37% | 0.05 |
IKNA closed up 0.38 percent on Wednesday, May 15, 2024, on 54 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 3.37% | |
| Shooting Star Candlestick | Bearish | 3.37% | |
| Bollinger Band Squeeze | Range Contraction | 3.37% | |
| Doji - Bearish? | Reversal | 3.37% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 3.37% | |
| Up 3 Days in a Row | Strength | 3.37% | |
| Upper Bollinger Band Touch | Strength | 3.37% | |
| 20 DMA Support | Bullish | 3.76% | |
| Bollinger Band Squeeze | Range Contraction | 3.76% | |
| NR7 | Range Contraction | 3.76% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 1 hour ago |
| Outside Day | about 1 hour ago |
| 50 DMA Resistance | about 3 hours ago |
| Rose Above Upper Bollinger Band | about 3 hours ago |
| Rose Above 50 DMA | about 3 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.35 |
| 52 Week Low | 1.02 |
| Average Volume | 277,547 |
| 200-Day Moving Average | 2.51 |
| 50-Day Moving Average | 1.38 |
| 20-Day Moving Average | 1.32 |
| 10-Day Moving Average | 1.34 |
| Average True Range | 0.08 |
| RSI (14) | 49.75 |
| ADX | 12.63 |
| +DI | 19.43 |
| -DI | 12.51 |
| Chandelier Exit (Long, 3 ATRs) | 1.18 |
| Chandelier Exit (Short, 3 ATRs) | 1.47 |
| Upper Bollinger Bands | 1.38 |
| Lower Bollinger Band | 1.26 |
| Percent B (%b) | 0.6 |
| BandWidth | 9.47 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0048 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.43 | ||||
| Resistance 3 (R3) | 1.43 | 1.41 | 1.41 | ||
| Resistance 2 (R2) | 1.41 | 1.39 | 1.41 | 1.40 | |
| Resistance 1 (R1) | 1.37 | 1.37 | 1.36 | 1.37 | 1.40 |
| Pivot Point | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 |
| Support 1 (S1) | 1.31 | 1.33 | 1.30 | 1.31 | 1.27 |
| Support 2 (S2) | 1.29 | 1.31 | 1.29 | 1.27 | |
| Support 3 (S3) | 1.25 | 1.29 | 1.26 | ||
| Support 4 (S4) | 1.25 |
